NYSE:VRX - Valeant Pharmaceuticals Intl Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.27 -0.45 (-1.82 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$24.27
Today's Range$23.82 - $24.47
52-Week Range$10.94 - $27.79
Volume5.80 million shs
Average Volume8.74 million shs
Market Capitalization$8.63 billion
P/E Ratio6.34
Dividend YieldN/A
Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio5.59
Current Ratio1.18
Quick Ratio0.92


Trailing P/E Ratio6.34
Forward P/E Ratio7.29
P/E Growth0.37

Sales & Book Value

Annual Sales$8.72 billion
Price / Sales0.97
Cash Flow$12.2576 per share
Price / Cash1.98
Book Value$17.05 per share
Price / Book1.42


EPS (Most Recent Fiscal Year)$3.83
Net Income$2.40 billion
Net Margins-10.65%
Return on Equity27.87%
Return on Assets3.58%


Outstanding Shares349,300,000

The Truth About Cryptocurrencies

Valeant Pharmaceuticals Intl (NYSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals Intl's earnings last quarter?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.29. The specialty pharmaceutical company had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The business's quarterly revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.79 EPS. View Valeant Pharmaceuticals Intl's Earnings History.

What price target have analysts set for VRX?

19 brokers have issued 12 month price targets for Valeant Pharmaceuticals Intl's shares. Their predictions range from $9.00 to $45.00. On average, they expect Valeant Pharmaceuticals Intl's share price to reach $20.5882 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

What are Wall Street analysts saying about Valeant Pharmaceuticals Intl stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals Intl stock:
  • 1. HC Wainwright analysts commented, "Exchange NYSE Value (M) $31,421.0 Market Cap (M) $7,064 Public Market Float (M) 329.9 Shares Outstanding (M) 348.8 3 Interest (M) 40.90 Cash (M) $909.0 Total Debt (M) $25,266.0 Year – (0.25) FY 6.86 (7.48) (1.32) FY P/E 3.0x NM NM Year – 2,290.0 FY 8,724.0 8,325.0 8,810.0 30 25 20 15 10 0 Vol." (5/7/2018)
  • 2. According to Zacks Investment Research, "Valeant’s Bausch + Lomb/International segment and Salix businesses are doing well and should propel the top-line in the coming quarters. The approval of new drugs should boost the top line. After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Shares of the company have outperformed the industry in the last six months. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay lower debt is commendable. As of Feb 28, 2018, the company reduced total debt by approximately $6.7 billion since the end of first-quarter 2016. The dermatology business remains challenging and is expected to decline in 2018 as compared to 2017.  The guidance for 2018 was disappointing. Hence, it might be a while before the company turn arounds as management had projected." (4/2/2018)
  • 3. Cantor Fitzgerald analysts commented, "There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning." (1/19/2018)

Are investors shorting Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 18,097,653 shares, a decrease of 15.9% from the April 30th total of 21,514,198 shares. Based on an average trading volume of 13,863,988 shares, the days-to-cover ratio is currently 1.3 days. Approximately 5.3% of the shares of the stock are short sold. View Valeant Pharmaceuticals Intl's Current Options Chain.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)

Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?

Media coverage about VRX stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Valeant Pharmaceuticals Intl earned a media sentiment score of 0.13 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 47.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Valeant Pharmaceuticals Intl's major shareholders?

Valeant Pharmaceuticals Intl's stock is owned by many different of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.63%), CIBC World Markets Inc. (0.97%), Fosun International Ltd (0.50%), Chou Associates Management Inc. (0.47%), Legal & General Group Plc (0.42%) and Private Management Group Inc. (0.36%). Company insiders that own Valeant Pharmaceuticals Intl stock include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals Intl.

Which major investors are selling Valeant Pharmaceuticals Intl stock?

VRX stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, OppenheimerFunds Inc., Schroder Investment Management Group, Hsbc Holdings PLC, Legal & General Group Plc, Vertex One Asset Management Inc., Swiss National Bank and Blair William & Co. IL. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

Which major investors are buying Valeant Pharmaceuticals Intl stock?

VRX stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Chou Associates Management Inc., O Shaughnessy Asset Management LLC, Dimensional Fund Advisors LP, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Point72 Asset Management L.P., Miracle Mile Advisors LLC and CIBC Asset Management Inc. Company insiders that have bought Valeant Pharmaceuticals Intl stock in the last two years include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

How do I buy shares of Valeant Pharmaceuticals Intl?

Shares of VRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of VRX stock can currently be purchased for approximately $24.27.

How big of a company is Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl has a market capitalization of $8.63 billion and generates $8.72 billion in revenue each year. The specialty pharmaceutical company earns $2.40 billion in net income (profit) each year or $3.83 on an earnings per share basis. Valeant Pharmaceuticals Intl employs 20,700 workers across the globe.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The specialty pharmaceutical company can be reached via phone at 514-744-6792 or via email at [email protected]

MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,252 (Vote Outperform)
Underperform Votes:  1,110 (Vote Underperform)
Total Votes:  2,362
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.